Energy metabolism and nutritional status in hospitalized patients with lung cancer

Yumi Takemura,¹ Masaya Sasaki,¹* Kenichi Goto,² Azusa Takaoka,¹ Akiko Ohi,¹ Mika Kurihara,¹ Naoko Nakanishi,¹ Yasutaka Nakano² and Jun Hanaoka³

¹Division of Clinical Nutrition, ²Division of Respiratory Medicine and ³Department of Thoracic Surgery, Shiga University of Medical Science, Seta-Tsukinowa, Otsu, Shiga 520-2192, Japan

(Received 4 January, 2016; Accepted 13 January, 2016; Published online 26 July, 2016)

This study aimed to investigate the energy metabolism of patients with lung cancer and the relationship between energy metabolism and proinflammatory cytokines. Twenty-eight patients with lung cancer and 18 healthy controls were enrolled in this study. The nutritional status upon admission was analyzed using nutritional screening tools and laboratory tests. The resting energy expenditure and respiratory quotient were measured using indirect calorimetry, and the predicted resting energy expenditure was calculated using the Harris-Benedict equation. Energy expenditure was increased in patients with advanced stage disease, and there were positive correlations between measured resting energy expenditure/predicted resting energy expenditure and interleukin-6 levels. There was significant correlation between body mass index and plasma interleukin-6 levels and between predicted resting energy expenditure and interleukin-6 levels. These results indicate that energy expenditure changes significantly with lung cancer stage and that plasma interleukin-6 levels affect energy metabolism and dietary intake. Thus, nutritional management that considers the changes in energy metabolism is important in patients with lung cancer.

Key Words: energy metabolism, nutritional status, indirect calorimetry, lung cancer

Malnutrition is an important problem occurring in patients with cancer and is associated with negative consequences, such as poor prognosis and quality of life. Severe weight loss has been found in 30% of newly detected patients with lung cancer. This phenomenon is thought to be caused by a disturbed energy balance. In other words, body weight is reduced by a negative balance between dietary intake and energy expenditure. Certainly, malnutrition results from a decrease in dietary intake and/or increased energy expenditure. There have been numerous studies on energy metabolism in patients with cancer; however, controversial conclusions have been reported. It has been reported that energy expenditure is elevated in patients with lung cancer or pancreatic cancer. Furthermore, Hansell et al. reported that higher resting energy expenditure (REE) was a poor prognostic indicator in patients with lung cancer. In contrast, it has been reported that energy expenditure is unchanged in patients with gastric cancer or colorectal cancer. Recently, Cao et al. reported that patients with advanced cancer had elevated energy expenditure, based on a study of 714 patients with cancer and 642 controls. In their report, patients with esophageal cancer, gastric cancer, pancreatic cancer, and non-small cell lung cancer showed elevated energy expenditure, but patients with colorectal cancer did not show any significant differences in energy metabolism from the controls. The type or stage of cancer may affect energy metabolism.

It has been suggested that systemic inflammatory mediators influence the energy metabolism of patients with cancer. In particular, cachexia is most pronounced in end-stage diseases that tend to associate with chronic inflammation, such as in cancer, chronic heart failure, or acquired immune deficiency disease. Proinflammatory cytokines such as interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α), and IL-6 must play a key role in cancer cachexia. Cytokines are proteins that are predominantly synthesized and released from immune cells. However, changes in the levels of these mediators in peripheral blood do not occur in parallel. Plasma IL-6 levels are reported to be increased in patients with cancer. In contrast, conflicting results are reported regarding the plasma levels of TNF-α. The paradoxical changes in the levels of these proinflammatory cytokines are recognized to result from differences in their half-lives. Biologically active TNF-α is difficult to detect because of its short half-life and its formation of complexes with soluble TNF-α receptors. Agnes et al. examined the plasma levels of the soluble TNF-α receptor and clarified that TNF-α had the potential to affect energy expenditure in patients with lung cancer.

Recently, we used indirect calorimetry to examine the energy expenditure of patients with inflammatory bowel disease. Our results clearly showed that IL-6, but not TNF-α, affected the energy metabolism of patients with inflammatory bowel disease. Here, we are the first to describe the nutritional status and REE as well as their relationships with systemic mediators such as proinflammatory cytokines, leptin, and ghrelin in patients with lung cancer.

Subjects and Methods

Patients. Twenty-eight patients with lung cancer (22 men and 6 women; mean age, 69.0 ± 10.9 years) were enrolled in this study. The patients were admitted to the Shiga University of Medical Science Hospital between July 2014 and June 2015. All patients had histologically documented tumors and had not undergone surgery. Sixteen patients who received chemotherapy had passed more than 1 month since their last treatment. All 18 healthy controls (9 men and 9 women; mean age, 65.1 ± 9.7 years) were volunteers; some of them had well-controlled hyperlipidemia or gastric ulcer scar. None of them had malignant or inflammatory disease. The ethics committee of the Shiga University of Medicine approved this study.

*To whom correspondence should be addressed. E-mail: sasaki@belle.shiga-med.ac.jp
Methods. The following values were measured upon admission.

(1) Nutritional screening: Subjective global assessment (SGA),(22,23) malnutrition universal screening tool (MUST), (24) nutritional risk screening 2002 (NRS2002), (25) and modified Glasgow prognostic score (mGPS). (26)

(2) Anthropometrics: Height (cm), weight (kg), and body mass index (BMI; kg/m²).

(3) Laboratory tests: Total protein level (g/dl), serum albumin (g/dl), total cholesterol (mg/dl), C-reactive protein (mg/dl), and total lymphocyte count.

(4) Bioelectrical impedance analysis: The percent of body fat (%) and fat-free mass (kg).

(5) Proinflammatory cytokines: Plasma IL-6 levels (pg/dl) and TNF-α levels (pg/dl) were determined using commercially available enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems, Minneapolis, MN).

(6) Appetite-controlling hormones: Plasma leptin levels (ng/ml) and acylated ghrelin levels were measured using radioimmunoassay. Plasma acylated ghrelin levels were measured using the active Ghrelin ELISA kit (LSI Medience Corporation, Tokyo, Japan).

(7) Intake: Dietary intake was calculated by an average of the intake over two days (kcal/day), and recommended energy need was calculated by multiplying the measured resting energy expenditure (mREE) by the active factor 1.3. The adequacy of energy intake was calculated as (dietary intake/recommended need) × 100 (%).

Indirect calorimetry. The mREE (kcal/kg/day), respiratory quotient (RQ), carbohydrate oxidation, and fat oxidation were measured via computed open-circuit indirect calorimetry (AE-300S, Minato Medical Science Co., Osaka, Japan). (21,27–31) Indirect calorimetry was performed in the hospital room after 8 h of fasting. Period flow and gas calibration were performed prior to all measurements. After resting for 30 min, the patients were assessed in a supine position using a facemask. A pump drew ambient air through a facemask at a constant rate. After equilibrium was reached for 10 min, respiratory exchange was performed continuously over 30 min. The mREE and RQ data were obtained every minute.

The mREE was calculated from the oxygen consumption (VO₂) and carbon dioxide production (VCO₂) using the Weir equation:(32)

\[ \text{mREE} = (3.94 \times \text{VO}_2 + 1.11 \times \text{VCO}_2) \times 1.44. \]

The RQ measurement was calculated as \( \text{RQ} = \text{VCO}_2 / \text{VO}_2 \). The mREE was then compared with the predicted resting energy expenditure (pREE), which was calculated using the Harris–Benedict equation as follows: \( 13.75 \times W + 5.0 \times H - 6.75 \times A \) [age (year)].

Statistical analyses. The Mann–Whitney U test, the one-way analysis of variance, and the chi-squared test were used for the statistical analysis. Correlations were investigated by Spearman rank correlation tests. Values are expressed as the mean and standard deviation. A \( p \)-value of <0.05 was considered statistically significant.

Results

Patient characteristics. Patient’s characteristics are shown in Table 1. Staging of the carcinomas indicated that 9 patients had stage I, 1 patient had stage II, 6 patients had stage III, and 12 patients had stage IV tumors. There were no significant differences in mean age, height, body weight, or BMI between healthy controls and patients with lung cancer.

Nutritional screening. As shown in Table 2, we divided patients with lung cancer into three groups depending on staging; there were 10 patients in stages I and II, 6 patients in stage III, and 12 patients in stage IV. According to the SGA, 8.3% of stage IV patients were considered severely malnourished and 50% of them qualified as moderately malnourished. Stage IV patients tended to be qualified as malnourished more frequently than stage I and II or stage III patients, but there were no significant differences among the patients for these parameters (\( p = 0.395 \)). According to the MUST, 33.3% of stage III patients and 58.4% of stage IV patients were considered at high risk for malnutrition. According to the NRS2002, 16.7% of stage III patients and 50.0% of stage IV patients were considered nutritionally at risk. Stage IV patients were more frequently qualified at high risk by the MUST (\( p = 0.022 \)) and nutritionally at risk by the NRS2002 (\( p = 0.023 \)). According to the mGPS, 33.3% of stage III patients and 50.0% of stage IV patients were considered to belong to the “Alb <3.5 g/dl and CRP ≥0.5 mg/dl” group. These percentages tended to be higher than those of the stage I and II patients (\( p = 0.077 \)).

Laboratory tests, inflammatory cytokines, and appetite-controlling hormones. As shown in Table 3, serum albumin in stage IV patients (3.3 ± 0.8 g/dl) was significantly lower than in stage I and II patients (4.0 ± 0.4 g/dl). Total cholesterol in stage IV

---

Table 1. Patients characteristics

| Characteristics | Healthy control | Lung cancer patient | \( p \) value |
|----------------|-----------------|---------------------|--------------|
| Patients number (male/female) | 18 (9/9) | 28 (22/6) | 0.180 |
| Age (year) | 65.1 ± 9.7 | 69.0 ± 10.9 | 0.937 |
| Height (cm) | 162.0 ± 9.4 | 161.6 ± 9.05 | 0.451 |
| Body weight (kg) | 61.1 ± 9.8 | 59.4 ± 13.5 | 0.636 |
| BMI (kg/m²) | 23.2 ± 2.1 | 22.6 ± 4.1 | 0.555 |

Histology

| Histology | | |
|-----------|-----------------|------------------|
| AC | 9 | 17 |
| SCC | 7 | |
| SCLC | 1 | |
| NSCLC | 2 | |
| Carcinoid | 1 | |

Staging

| Staging | I | II | III | IV |
|---------|---|----|-----|----|
| Number | 9 | 1 | 6 | 12 |

B: body mass index; AC, adenocarcinoma; SCC, squamous cell carcinoma; SCLC, small cell lung cancer; NSCLC, non-small cell lung cancer. Each value represents the mean ± SD.

---

Y. Takemura et al.  | J. Clin. Biochem. Nutr. | September 2016 | vol. 59 | no. 2 | 123

©2016 JCBN
patients (158.1 ± 26.6 mg/dl) was significantly lower than in stage I and II patients (206.9 ± 40.2 mg/dl). The C-reactive protein level in stage IV patients (3.7 ± 4.2 mg/dl) was significantly greater than in stage I and II patients (0.1 ± 0.1 mg/dl) and stage III patients (0.7 ± 0.7 mg/dl).

The plasma IL-6 level tended to be higher in stage IV patients (30.3 ± 40.2 pg/ml) than in stage I and II patients (14.6 ± 37.8 pg/ml) or in stage III patients (5.4 ± 5.1 pg/ml), but the differences were not significant. There were no significant differences or tendencies in plasma TNF-α, leptin, or acylated ghrelin levels among these three groups.

### Energy metabolism

As shown in Table 4, the mREE/body weight and mREE/pREE in healthy controls were 22.0 ± 2.6 kcal/kg/day and 1.05 ± 0.10, respectively. In stage I and II patients, the mREE/body weight was 20.9 ± 2.0 kcal/kg/day and the mREE/pREE was 1.02 ± 0.06. In stage III patients, the mREE/body weight was 21.8 ± 3.7 kcal/kg/day and the mREE/pREE was 1.07 ± 0.13. In stage IV patients, the mREE/body weight was 25.0 ± 5.5 kcal/kg/day and the mREE/pREE was 1.14 ± 0.14. The mean mREE/body weight in stage IV patients was significantly higher than in healthy controls (p = 0.033) or than in stage I and II patients (p = 0.012). Mean mREE/pREE in stage IV patients was higher than in the healthy controls (p = 0.059) or in stage I and II patients (p = 0.031). However, there were no significant differences in RQ, glucose, or fat oxidation between the patients with lung cancer and healthy controls.

There were positive correlations between plasma IL-6 levels and mREE/body weight and between plasma IL-6 levels and mREE/pREE. However, there was no significant correlation between plasma TNF-α levels and mREE/body weight or between plasma TNF-α levels and mREE/pREE (Fig. 1).

### Dietary intake and the adequacy of energy intake

Dietary intake was 1,600 ± 202 kcal/day in stage I and II patients, 1,391 ± 329 kcal/day in stage III patients, and 1,271 ± 458 kcal/day in stage IV patients. Sixty percent of stage I and II patients, 83% of stage III patients, and 75% of stage IV patients

---

**Table 2. Nutritional screening**

|                     | Stage I and II | Stage III | Stage IV | p value |
|---------------------|---------------|-----------|----------|---------|
| Patients number     | 10            | 6         | 12       |         |
| SGA                 |               |           |          |         |
| Well nourished      | 70.0%         | 83.3%     | 41.7%    | 0.395   |
| Moderately malnourished | 30.0%     | 16.7%     | 50.0%    |         |
| Severely malnourished | 0          | 0         | 8.3%     |         |
| MUST                |               |           |          |         |
| Low risk            | 100.0%        | 50.0%     | 33.3%    | 0.022   |
| Medium risk         | 0             | 16.7%     | 8.3%     |         |
| High risk           | 0             | 33.3%     | 58.4%    |         |
| NRS2002             |               |           |          |         |
| Without nutritional risk | 100.0% | 83.3%     | 50.0%    | 0.023   |
| With nutritional risk| 0         | 16.7%     | 50.0%    |         |
| mGPS                |               |           |          |         |
| Alb ≥3.5 g/dl and CRP <0.5 mg/dl | 90.0% | 50.0% | 25.0% | 0.077 |
| Alb <3.5 g/dl and CRP <0.5 mg/dl | 10.0% | 0 | 8.3% |         |
| Alb ≥3.5 g/dl and CRP ≥0.5 mg/dl | 0 | 16.7% | 16.7% |         |
| Alb <3.5 g/dl and CRP ≥0.5 mg/dl | 0 | 33.3% | 50.0% |         |

SGA, subjective global assessment; MUST, malnutrition universal screening tool; NRS2002, nutritional risk screening 2002; mGPS, modified Glasgow prognostic score.

**Table 3. Laboratory tests and proinflammatory cytokines, appetite-controlling hormones**

|                      | Stage I and II | Stage III | Stage IV |
|----------------------|----------------|-----------|----------|
| **Laboratory tests** |                |           |          |
| TP (g/dl)            | 6.9 ± 0.5      | 7.0 ± 0.5 | 6.9 ± 0.6 |
| Alb (g/dl)           | 4.0 ± 0.4      | 3.8 ± 0.5 | 3.3 ± 0.8 |
| T-cho (mg/dl)        | 206.9 ± 40.2   | 182.8 ± 31.2 | 158.1 ± 26.6* |
| CRP (mg/dl)          | 0.1 ± 0.1      | 0.7 ± 0.7 | 3.7 ± 4.2* |
| TLC (/μl)            | 1,588.6 ± 558.7 | 1,466.5 ± 190.6 | 1,212.4 ± 525.8 |
| **Proinflammatory cytokines** |            |           |          |
| IL-6 (pg/ml)         | 14.6 ± 37.8    | 5.4 ± 5.1 | 30.3 ± 40.2 |
| TNF-α (pg/dl)        | 2.2 ± 0.9      | 1.8 ± 0.7 | 2.7 ± 2.3 |
| **Appetite-controlling hormones** |            |           |          |
| Leptin (ng/ml)       | 5.3 ± 7.4      | 9.5 ± 7.4 | 10.1 ± 16.5 |
| Acylated ghrelin (fmol/ml) | 11.2 ± 10.0 | 19.0 ± 13.7 | 23.9 ± 19.5 |

TP, total protein; Alb, albumin; T-cho, total cholesterol; CRP, C-reactive protein; TLC, total lymphocyte count; IL-6, interleukin-6; TNF-α, tumor necrosis factor-α. Each value represents the mean ± SD. *p<0.05 compared with lung cancer stage I and II. **p<0.05 compared with lung cancer stage III.
Unlike healthy controls, patients with lung cancer eat less than their nutritional need.

As shown in Fig. 2, there were positive correlations between plasma leptin levels and BMI and between plasma leptin levels and percent body fat. However, there was no significant correlation between plasma leptin levels and dietary intake or between plasma leptin levels and the percent of recommended needs.

As shown in Fig. 3, there was a negative correlation between plasma acylated ghrelin levels and BMI. There was also a negative tendency of correlation between plasma acylated ghrelin levels and the percent body fat ($p = 0.090$). However, there were no significant correlations between plasma acylated ghrelin levels and dietary intake or between plasma acylated ghrelin levels and the rate of energy intake.

There were significant negative correlations between plasma IL-6 levels and dietary intake and between plasma IL-6 levels and the rate of energy intake. However, there were no significant

---

### Table 4. Energy metabolism

|                        | Healthy controls | Stage I and II | Stage III | Stage IV |
|------------------------|------------------|---------------|-----------|----------|
| mREE (kcal/day)        | 1,335 ± 215      | 1,260 ± 173   | 1,413 ± 278 | 1,343 ± 340 |
| pREE (kcal/day)        | 1,274 ± 169      | 1,240 ± 168   | 1,311 ± 173 | 1,189 ± 292 |
| mREE/BW (kcal/kg/day)  | 22.0 ± 2.6       | 20.9 ± 2.0    | 21.8 ± 3.7  | 25.0 ± 5.5<sup>a</sup> |
| mREE/pREE              | 1.05 ± 0.10      | 1.02 ± 0.06   | 1.07 ± 0.13  | 1.14 ± 0.14<sup>a</sup> |
| RQ                     | 0.84 ± 0.06      | 0.80 ± 0.04   | 0.81 ± 0.05  | 0.81 ± 0.08  |
| C (g/day)              | 152.3 ± 78.3     | 97.5 ± 30.6   | 128.1 ± 84.4 | 107.1 ± 71.2  |
| F (g/day)              | 75.0 ± 30.1      | 90.6 ± 27.6   | 93.4 ± 28.9  | 96.1 ± 50.1  |

mREE, measured resting energy expenditure; pREE, predicted resting energy expenditure; BW, body weight; RQ, respiratory quotient; C, carbohydrate oxidation; F, fat oxidation. Each value represents the mean ± SD. <sup>a</sup>p<0.05 compared with healthy controls. <sup>b</sup>p<0.05 compared with lung cancer stage I and II.

---

**Fig. 1.** Correlations between plasma interleukin-6 (IL-6) levels and tumor necrosis factor-α (TNF-α) levels with measured resting energy expenditure (mREE)/body weight or mREE/predicted resting energy expenditure (mREE/pREE) in patients with lung cancer. Plasma IL-6 levels exhibited a positive correlation with mREE/body weight (A) and with mREE/pREE (B). However, there was no significant correlation between plasma TNF-α levels and mREE/body weight (C) or mREE/pREE (D).
correlations between plasma TNF-α levels and dietary intake or between plasma TNF-α levels and the rate of energy intake (Fig. 4).

Discussion

In this study, we demonstrated that REE was elevated in patients with advanced lung cancer and that this change in energy metabolism was significantly associated with plasma levels of the proinflammatory cytokine IL-6. It has been generally accepted that the proinflammatory cytokines IL-1β, IL-6, and TNF-α are connected with malnutrition in patients with cancer. Further- more, these cytokines play important roles in the pathogenesis of cachexia. DeJong et al. showed that plasma levels of the systemic inflammatory mediators IL-6 and soluble TNF-α receptor correlated with an increased ubiquitin level, which played an important role in muscle wasting in cachexia. Thus, proinflammatory cytokines certainly induce muscle wasting in patients with cancer. In particular, increased plasma IL-6 levels were reported in patients with lung cancer, and there are some reports of a significant relationship between systemic inflammation and REE. Previously, Kotani et al. reported that mREE/pREE exhibited a significant correlation with IL-6 level but was not correlated with TNF-α levels in surgical trauma. In the present study, we clearly demonstrated that IL-6, but not TNF-α, played a main role in the negative balance of energy metabolism in patients with lung cancer. This phenomenon is quite similar to our recent report concerning energy metabolism in patients with inflammatory bowel disease. Certainly, TNF-α has been reported to be a strong inducer of IL-6 production and at least some of the elevation of serum IL-6 levels depends upon TNF-α. However, it has been reported that biologically active TNF-α is difficult to detect because of its short half-life and the formation of complexes with soluble TNF-α receptors. These characteristics of TNF-α may impact the serum levels of IL-6 and TNF-α in our present study.

Körber et al. reported that lipid utilization was increased in patients with cancer who were losing weight. We recently reported similar results in patients with Crohn’s disease receiving anti-TNF-α therapy. Glucose oxidation may be inhibited by proinflammatory cytokines such as IL-6 or TNF-α. However, in our present study, there were no significant differences in glucose or fat oxidations between patients with lung cancer and healthy controls.

In this study, we examined the levels of leptin and ghrelin in patients with lung cancer. We demonstrated that the plasma leptin level significantly correlated with BMI in patients with lung cancer. Tas et al. also reported that plasma leptin levels were significantly lower in patients with lung cancer than in healthy controls and that the plasma leptin level significantly decreased after chemotherapy. Leptin is derived from the adipose tissue and plays a role in inhibiting energy intake. We speculate that reduced leptin secretion may represent a compensatory mechanism during energy imbalance. In contrast, ghrelin is derived from the stomach...
and is one of the hormones involved in controlling body weight, insulin secretion, and appetite regulation. Of the two circulating forms of ghrelin, acylated and des-acylated, the acylated form is thought to be essential for the biological activity of ghrelin. Previously, Shimizu et al. (44) reported that plasma ghrelin levels were significantly higher in patients with lung cancer cachexia than in healthy controls or in patients with non-cachexia lung cancer. Furthermore, we demonstrated that the plasma acylated ghrelin level negatively correlated with BMI. From these results, increased acylated ghrelin may also represent a compensatory mechanism during energy imbalance. Similar findings have been reported in patients with chronic obstructive pulmonary disease. Takabatake et al. (45) also reported significant correlations between plasma leptin levels (log transformed) and BMI or the percent of fat in patients with chronic obstructive pulmonary disease. Itoh et al. (46) reported that plasma ghrelin levels were significantly higher in underweight patients with chronic obstructive pulmonary disease. Changes in plasma leptin and acylated ghrelin levels follow the same pattern in patients with lung cancer that they do in those with chronic obstructive pulmonary disease. Leptin has been reported as a candidate factor of increasing REE (47). However, no significant relationship between mREE and plasma leptin or ghrelin levels was seen in this study. We could not demonstrate that these signals affected energy expenditure itself in patients with lung cancer. The number of patients in this study was not large, and only two patients revealed cachexic findings. Recently, Fearon et al. (48) defined and classified cancer cachexia into three stages of clinical relevance: pre-cachexia, cachexia, and refractory cachexia. It may be necessary to investigate energy metabolism in a large number of patients with advanced lung cancer according to these three stages.

Anorexia and reduced food intake are among the host physiological responses to tumors, and anorexia is an important symptom in patients with advanced cancer. In patients with cancer, anorexia contributes to the development of malnutrition or cachexia. Multiple factors, such as proinflammatory cytokines, eicosanoids, and hormones, have been connected with cancer anorexia. Our results confirm that plasma IL-6 correlates with reduced food intake, and proinflammatory cytokines play a significant role in energy imbalance. Trikha et al. (49) reported that anti-IL-6 monoclonal antibody therapy decreased the incidence of cancer-related anorexia and cachexia. This therapy may be useful in treating malnutrition in patients with lung cancer. The usefulness of fish oil for patients with pancreatic or colorectal cancer has recently been reported. (50, 51) Fish oils, such as eicosapentaenoic acid, may inhibit the function of proinflammatory cytokines. (52–54) Some nutritional factors, such as eicosapentaenoic acid, may be useful in the nutritional management of patients with lung cancer.

In conclusion, REE was increased in patients with advanced lung cancer, and the proinflammatory cytokine IL-6 affected this change in energy metabolism. Leptin and acylated ghrelin were secreted as a compensatory mechanism during energy imbalance.

Fig. 3. Correlation between acylated ghrelin levels and body mass index (BMI), the percent of body fat (%FAT), intake and the percent of recommended needs. Acylated ghrelin levels exhibited negative correlation with BMI (A) and %FAT ($p = 0.090$) (B). However, there was no significant correlation between acylated ghrelin levels and intake (C) or the percent of recommended needs (D).
Nevertheless, reduced appetite was seen in advanced patients with lung cancer. From our results, IL-6 may also affect this cancer-related anorexia. Therefore, nutritional management that considers the changes in energy metabolism is important in patients with lung cancer.

Conflict of Interest
No potential interests of conflict were disclosed.

References
1 Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980; 69: 491–497.
2 Chute CG, Greenberg ER, Baron J, Korson R, Baker J, Yates J. Presenting conditions of 1539 population-based lung cancer patients by cell type and stage in New Hampshire and Vermont. Cancer 1985; 56: 2107–2111.
3 Staal-van den Brekel AJ, Schols AM, ten Velde GP, Buurman WA, Wouters EF. Analysis of the energy balance in lung cancer patients. Cancer Res 1994; 54: 6430–6433.
4 Moses AW, Slater C, Preston T, Barber MD, Fearon KC. Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer 2004; 90: 996–1002.
5 Falconer JS, Fearon KC, Piester CE, Ross JA, Carter DC. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 1994; 219: 325–331.
6 Hansell DT, Davies JW, Burns HJ. The relationship between resting energy expenditure and weight loss in benign and malignant disease. Ann Surg 1986; 203: 240–245.
7 Fredrix EW, Soeters PB, Wouters EF, Deereenberg IM, von Meyenfeldt MF, Saris WH. Effect of different tumor types on resting energy expenditure. Cancer Res 1991; 51: 6138–6141.
8 Jatoi A, Daly BD, Hughes V, Dallal GE, Roubenoff R. The prognostic effect of increased resting energy expenditure prior to treatment for lung cancer. Lung Cancer 1999; 23: 153–158.
9 Cao DX, Wu GH, Zhang B, et al. Resting energy expenditure and body composition in patients with newly detected cancer. Clin Nutr 2010; 29: 72–77.
10 Gelin J, Moldawer LL, Lonnroth C, Sherry B, Chizzonite R, Lundholm K. Role of endogenous tumor necrosis factor α and interleukin 1 for experimental tumor growth and the development of cancer cachexia. Cancer Res 1991; 51: 415–421.
11 Strassmann G, Fong M, Kenney JS, Jacob CO. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 1992; 89: 1681–1684.
12 Tisdale MJ. Biology of cachexia. J Natl Cancer Inst 1997; 89: 1763–1773.
13 Suzuki H, Asakawa A, Amstani H, Nakanura N, Imai A. Cancer cachexia--pathophysiology and management. J Gastroenterol 2013; 48: 574–594.
14 Dosquet C, Schaeetz A, Faucher C, et al. Tumor necrosis factor-α, interleukin-
β- and interleukin-6 in patients with renal cell carcinoma. Eur J Cancer 1994; 30A: 162–167.

15 Plante M, Rubin SC, Wong GW, Federici MG, Finsand CL, Gasti GA. Interleukin-6 level in serum and ascites as prognostic factor in patients with epithelial ovarian cancer. Cancer 1994; 73: 1882–1888.

16 Aderka D, Fisher S, Levo Y, Holtmann H, Hahn T, Wallach D. Cachectin/ tumor-necrosis-factor production by cancer patients. Lancet 1985; 2: 1190.

17 Balkwill F, Osborne R, Burke F, et al. Evidence for tumor necrosis factor/ cachectin production in cancer. Lancet 1987; 2: 1229–1232.

18 Engelberts I, Möller A, Schoen GJ, van der Linden CJ, Buurman WA. Comparison of energy metabolism and nutritional status of hospitalized patients with Crohn’s disease and those with ulcerative colitis. J Clin Biochem Nutr 2015; 56: 208–214.

19 Baker JP, Detsky AJ, Wolman SL, Wesson DE, Jeejeebhoy KN. The effect of a bolus injection of TNF-α and IL-1β on hepatic energy metabolism in rats. J Surg Res 1995; 58: 509–515.

20 Körber J, Price J, Sheehan C, Malone F, Rietbrock J, et al. Increased lipid utilization in patients with systemic inflammatory response syndrome in lung cancer patients. J Clin Oncol 1995; 13: 2600–2605.

21 Takaoka A, Sasaki M, Kurihara M, et al. Comparison of energy metabolism and nutritional status of hospitalized patients with Crohn’s disease and those with ulcerative colitis. J Clin Biochem Nutr 2015; 56: 208–214.

22 Baker JP, Detsky AS, Wesson DE, et al. Nutritional assessment: a comparison of clinical judgment and objective measurements. N Engl J Med 1982; 306: 969–972.

23 Detsky AS, Baker JP, Mendelson RA, Wolman SL, Wesson DE, Jeejeebhoy KN. Evaluating the accuracy of nutritional assessment techniques applied to hospitalized patients: methodology and comparisons. JPEN J Parenter Enteral Nutr 1984; 8: 153–159.

24 Stratton RJ, Hackston A, Longmore D, et al. Malnutrition in hospital outpatients and inpatients: prevalence, concurrent validity and ease of use of the ‘malnutrition universal screening tool’ (‘MUST’) for adults. Br J Nutr 2004; 92: 799–808.

25 Kandrup J, Allison SP, Elia M, et al. ESPEN guidelines for nutrition screening 2002. Clin Nutr 2003; 22: 415–421.

26 Miki C, Kusunoki M. Perioperative nutritional management in various clinical conditions: diseases of lower digestive system. Nihon Geka Gakkai Zasshi 2010; 111: 368–372 (in Japanese).

27 Sasaki M, Johtatsu T, Kurihara M, et al. Energy metabolism in Japanese patients with Crohn’s disease. J Clin Biochem Nutr 2010; 46: 68–72.

28 Sasaki M, Johtatsu T, Kurihara M, et al. Energy metabolism in Japanese patients with severe or moderate ulcerative colitis. J Clin Biochem Nutr 2010; 47: 32–36.

29 Nishida N, Sasaki M, Kurihara M, et al. Changes of energy metabolism, nutritional status and serum cytokine levels in patients with Crohn’s disease after anti-tumor necrosis factor-α therapy. J Clin Biochem Nutr 2013; 53: 122–127.

30 Okamoto H, Sasaki M, Johtatsu T, et al. Resting energy expenditure and nutritional status in patients undergoing transthoracic esophagectomy for esophageal cancer. J Clin Biochem Nutr 2011; 49: 169–173.

31 Inoue M, Sasaki M, Takaoka M, et al. Changes in energy metabolism after induction therapy in patients with severe or moderate ulcerative colitis. J Clin Biochem Nutr 2015; 56: 215–219.

32 Weir JB. New method for calculating metabolic rate with special reference to protein metabolism. J Physiol 1949; 109: 1–9.

33 Harris JA, Benedict FG. A biometric study of human basal metabolism. Proc Natl Acad Sci USA 1918; 4: 370–373.

34 Cahlin C, Körner A, Axelsson H, Wang W, Lundholm K, Svanberg E. Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-γ, and tumor necrosis factor α evaluated in gene knockout, tumor-bearing mice on C57 Bl Background and eicosanoid-dependent cachexia. Cancer Res 2000; 60: 5488–5493.

35 Dejong CH, Busquets S, Moses AG, et al. Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia. Oncol Rep 2005; 14: 257–263.

36 Yangawara H, Sone S, Takashiki Y, et al. Serum levels of interleukin 6 in patients with lung cancer. Br J Cancer 1995; 71: 1095–1098.

37 Simons JP, Schols AM, Buurman WA, Wouters EF. Weight loss and low body cell mass in males with lung cancer: relationship with systemic inflammation, acute-phase response, resting energy expenditure, and catabolic and anabolic hormones. Clin Sci (Lond) 1999; 97: 215–223.

38 Kotani G, Usami M, Kasahara H, Saitoh Y. The relationship of IL-6 to hormonal mediators, fuel utilization, and systemic hypermetabolism after surgical trauma. Kobe J Med Sci 1996; 42: 187–205.

39 Shimada M, Andoh A, Hata K, et al. IL-6 secretion by human pancreatic periacinar myofibroblasts in response to inflammatory mediators. J Immunol 2002; 168: 861–868.

40 Körber J, Pricelius S, Heidrich M, Müller MJ, et al. Increased lipid utilization in weight losing and weight stable cancer patients with normal body weight. Eur J Clin Nutr 1999; 53: 740–745.

41 Jin MB, Shimahara Y, Yamaguchi T, et al. The effect of a bolus injection of TNF-α and IL-1β on hepatic energy metabolism in rats. J Surg Res 1995; 58: 509–515.

42 Kroder G, Bossenmaier B, Kellerman M, et al. Tumor necrosis factor-α and hyperglycaemia-induced insulin resistance. Evidence for different mechanisms and different effects on insulin signaling. J Clin Invest 1996; 97: 1471–1477.

43 Tas F, Durányildiz D, Argun A, et al. Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer. Med Oncol 2005; 22: 353–358.

44 Shimizu Y, Nagaya N, Isebo T, et al. Increased plasma ghrelin level in lung cancer cachexia. Clin Cancer Res 2003; 9: 774–778.

45 Takabatake N, Nakamura H, Abe S, et al. Circulating leptin in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159 (4 Pt 1): 1215–1219.

46 Itok T, Nagaya N, Yoshikawa M, et al. Elevated plasma ghrelin level in underweight patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 879–882.

47 Friedman JM, Halaus JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395: 763–770.

48 Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011; 12: 489–495.

49 Yanagawara H, Corrigan R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003; 9: 4653–4665.

50 Fearon KC, von Meyenfeldt MF, Moses AG, et al. Effect of protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 2003; 52: 1479–1486.

51 Lewis C, Xun P, Fly AD, Luo J, He K. Fish oil supplementation and quality of life in stage II colorectal cancer patients: a 24-month follow-up study. Nutr Cancer 2015; 67: 1219–1246.

52 Lee TH, Hoover RL, Williams JD, et al. Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monoocyte leukotriene generation and neutrophil function. N Engl J Med 1985; 312: 1217–1224.

53 Bousserouel S, Brouillet A, Bérézat G, Raymond M, Andréani M. Different effects on n-6 and n-3 polyunsaturated fatty acids on the activation of rat smooth muscle cells by interleukin-1 beta. J Lipid Res 2003; 44: 601–611.

54 Mickleborough TD, Tecklenburg SL, Montgomery GS, Lindley MR. Eicosapentaenoic acid is more effective than docosahexaenoic acid in inhibiting proinflammatory mediator production and transcription from LPS-induced human asthmatic alveolar macrophage cells. Clin Nutr 2009; 28: 71–77.